The aim of this retrospective single-center study was to evaluate the frequency of and identify risk factors for cardiac adverse events (CAEs) in consecutively transplanted AML patients treated with midostaurin and/or other FLT3 targeting agents. Here, FLT3 is linked to acute myeloid leukemia.